Developing effective treatments and understanding how the mechanism of the immune system have always been challenging for ...

Kuick Research Report Highlights Ongoing Developments In Molecular Switches Application Therapeutic Targets & Drug Delivery ...

NEWTON, MA, USA I 12, 2025 I Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and ...

New York–based hematologist-oncologist and clinical researcher works to lower the barriers to enrolling in clinical trials.

NEW YORK – Galapagos said on Monday that it has partnered with NecstGen, a contract development and manufacturing organization (CDMO), to support decentralized manufacturing of Galapagos' cell therapy ...

Orca Bio announces it met the primary endpoint in its pivotal Phase 3 clinical study for its lead allogeneic T-cell immunotherapy, Orca-T.

With positive mid-stage results in marginal zone lymphoma, Bristol Myers Squibb could soon add a new indication for the CAR T ...

With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in the most cancer types. | With another trial win, Bristol Myers Squibb is ...

Oct. 7, 2024 — Fratricide-resistant CD7 CAR-T therapy by NUS proves effective ... risk in children with standard risk B-cell acute lymphoblastic leukemia (SR B-ALL), the most common childhood ...

Laurie Adami's experience with CAR T-cell therapy highlights its potential in treating Non-Hodgkin Lymphoma, emphasizing the ...

University of Illinois Chicago scientists have redesigned a treatment for the most common pediatric leukemia to eliminate its severe side effects, like blood clots and liver damage.